Claims for Patent: 4,957,745
✉ Email this page to a colleague
Summary for Patent: 4,957,745
| Title: | Pharmaceutical preparation |
| Abstract: | Controlled release preparation containing a number of beads comprising a salt of metoprolo as the main soluble component, a method for the production thereof and the use in the treatment of cardiovascular disorders. |
| Inventor(s): | Jonsson; Ulf E. (Molndal, SE), Sandberg; John A. (Molndal, SE), Sjogren; John A. (Molnycke, SE) |
| Assignee: | Aktiebolaget Hassle (Molndal, SE) |
| Application Number: | 07/310,489 |
| Patent Claims: |
1. Controlled release preparation comprising a plurality of beads having a soluble component comprising at least 95% weight/weight of a salt of metoprolol which has a solubility of less
than 600 mg/ml in water at 25.degree. C. and a metoprolol permeable polymeric membrane coating surrounding each of said beads, said coating consisting essentially of ethylcellulose or a mixture of ethylcellulose and hydroxypropylmethylcellulose wherein
the coating is present in amounts such that the metoprolol is released through the coating over a period of at least 15 hours virtually independent of pH in the interval pH 1-8.
2. Preparation according to claim 1 wherein the size of the beads is in the range of 0.25-2 mm. 3. Preparation according to claim 2 wherein the size of the beads is in the range of 0.35-1.0 mm. 4. Preparation according to claim 1 wherein at least 50% of the dose of metoprolol is released at a rate of 3-7 w/w %/hour. 5. Preparation according to claim 1 wherein the salt of metoprolol has a solubility of 30-600 mg/ml. 6. Preparation according to claim 5 wherein the salt of metoprolol is formed of an organic carboxylic acid. 7. Preparation according to claim 6 wherein the salt of metoprolol is the succinate or fumarate of racemic metoprolol. 8. Preparation according to claim 6 wherein the salt of metoprolol is the bensoate or sorbate of the S-enantiomer of metoprolol. 9. Preparation according to claim 1 wherein the beads comprise at least 95 w/w % of metoprolol. 10. Preparation according to claim 1 wherein the beads further comprise an insoluble core disposed in the interior of the soluble component. 11. Preparation according to claim 10 wherein the insoluble cores have a size of 0.1-1.0 mm. 12. Preparation according to claim 10 wherein the insoluble cores have a size of 0.15-0.3 mm and are covered with a layer of the soluble component to give beads having a size of 0.35-1.0 mm. 13. Preparation according to claim 9 wherein the beads have a size of 0.35-1.0 mm. 14. Preparation according to claim 1 wherein polymeric membrane contains ethyl cellulose together with hydroxypropylmethyl cellulose. 15. A pharmaceutical preparation containing the controlled release preparation according to claim 1 filled into hard gelatine capsules. 16. A pharmaceutical preparation comprising the controlled release preparation according to claim 1 and pharmaceutical additives compressed to tablets which disintegrate to release the preparation when the tablets are brought into contact with gastro-intestinal fluids. 17. Method of producing a preparation according to claim 1 comprising spray coating beads comprising a salt of metoprolol with a membrane-forming solution consisting essentially of ethylcellulose. 18. A method for the treatment of cardiovascular disorders comprising administering a composition according to claim 1 to a host in need of such treatment in a therapeutically effective amount. 19. Preparation according to claim 10, wherein the insoluble cores have a size of 0.15-0.3 mm. 20. Preparation according to claim 1, wherein the amount of coating is such that at least 75% of the metoprolol is released over a period of 20 hours. 21. Preparation according to claim 1, wherein the soluble component comprises at least 95% w/w of the salt of metoprolol. |
